Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)

NCT00294164 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

245

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Human Immunodeficiency Virus Infections

Interventions

DRUG: Serostim®
DRUG: Placebo

Sponsor

EMD Serono